Health Press Release – Weekly Newsletter for December 13-20, 2010
Monday, December 20, 2010
Merck Serono and San Raffaele Scientific Institute to Collaborate on Research in Neurodegenerative Diseases
GENEVA, December 13, 2010 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today
announced a strategic collaboration with the Institute of Experimental
Neurology (INSpe) and the Department of Neurology of the San Raffaele
Scientific Institute (Milan, Italy) to advance clinical research projects in
multiple sclerosis and neurodegenerative diseases.
This collaboration follows previous agreements, …. Source : Gaea News Network.
Ocean Nutrition Canada Limited Announces Strategic Alliance with Wilmar International Limited – the World’s Largest Omega-3 EPA/DHA Food Company
Makers of Arawana Brand Cooking oil Bring a Healthier Product to Their Consumers
DARTMOUTH, Canada, December 14, 2010 – Ocean Nutrition Canada Limited (ONC), the
world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3(R)
brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid)
ingredients, is pleased to announce that it has entered into an exclusive
long term strategic agreement with Wilmar … Original source on Gaea Times at : Ocean Nutrition Canada Limited Announces Strategic Alliance with Wilmar International Limited – the World's Largest Omega-3 EPA/DHA Food Company.
SulAmerica Enters into Contract to Acquire Dental PLAN
The acquisition will increase dental care portfolio by more than 30%
SAO PAULO, December 14, 2010 – SulAmerica (BM&FBovespa: SULA11) announced today the signing of a share
purchase agreement for the acquisition of Dental PLAN Ltda., one of the major
dental care providers in the North and Northeast regions of Brazil, which has
also shown a significant growth …. Source article on Gaea Times at : SulAmerica Enters into Contract to Acquire Dental PLAN.
3D Keyhole Surgery at the Forefront of Cutting-edge Research
GUILDFORD, England, December 14, 2010 – Doctors will shortly be performing the world's first remote 3D keyhole
surgery during a symposium at the University of Surrey. Keyhole surgery -
where doctors operate on organs through a tiny incision – reduces the length
of hospital stays and post-operative complications. This also means that
patients experience less scarring and pain. … Read more >>.
Italy’s National Agency for Regional Health Services (Agenas) Names Zimmer(R) NexGen(R) LPS Knee the Most Cost-Effective Total Knee Replacement Implant
WINTERTHUR, Switzerland, December 14, 2010 – Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal
care, today announced that the Zimmer NexGen LPS knee was ranked the most
cost-effective multiradius design total knee replacement implant in Italy in
a recent health technology assessment by Italy's National Agency for Regional
Health Services.(1)
The assessment … Read the original article on Gaea Times at : Italy's National Agency for Regional Health Services (Agenas) Names Zimmer(R) NexGen(R) LPS Knee the Most Cost-Effective Total Knee Replacement Implant.
Cell Biosciences Announces US Patent Issuance
SANTA CLARA, California, December 14, 2010 – Cell Biosciences, Inc. today announced the issuance of Patent No.
7,846,676 for "Methods and Devices for Analyte Detection" by the United
States Patent and Trademark Office.
The patent represents a key element of intellectual property related to
NanoPro assay technology. It is one of several within a … Read : Cell Biosciences Announces US Patent Issuance.
Elsevier Launches Executable Paper Grand Challenge
Contest Created to Improve the way Scientific Information is Communicated and Used
NEW YORK, December 14, 2010 – Elsevier, a leading global publisher of scientific, technical and medical
information, announced today that it has launched a new competition that
invites scientists to improve how data intensive research is represented in a
scholarly journal article. The Elsevier Executable Paper …. Original source : Elsevier Launches Executable Paper Grand Challenge.
Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010
SAN DIEGO, December 14, 2010 – Amira Pharmaceuticals, Inc. announced today that it will present
preclinical and clinical data from its DP2 receptor antagonist program on
December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from
Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D.,
in a presentation titled "Discovery and optimization of a …. Read the original article : Amira Pharmaceuticals to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010.
The First Biotechnology Company That Measures Telomeres
Dr. Mar??a Blasco, the Bot??n Foundation and Matlin Associates Establish Life Length, S.L.
MADRID, December 15, 2010 – Life Length, S.L. is a new biotechnology company set up to
measure the length of telomeres which form caps at the end of chromosomes and
that have a fundamental role in avoiding the break down and the aging of
cells … Read more »»».
Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test “ColoPrint” in Journal of Clinical Oncology
Second Independent Validation Study of ColoPrint Selected for Oral Presentation and Press Conference at ASCO GI in January 2011
IRVINE, California and AMSTERDAM, December 15, 2010 – Agendia, a world leader in molecular cancer diagnostics,
announced today that together with principal investigators from Spain, the
UK, and the Netherlands, it has published the first independent validation
study of …. Original article : Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology.
Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering
AMSTERDAM, December 15, 2010 – The International Bionic Engineering Conference 2011 (
www.bionicengineeringconference.com/index.html) organised by Elsevier,
the leading publisher of scientific, technical and medical information
products and services, aims to bridge the gap between academic research and
industrial development in a field that is rapidly growing and gaining
recognition across many disciplines.
Intended as a common …. Source : Elsevier Bringing Together Thought Leaders and Experts for New International Conference in Bionic Engineering.
Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Potential Utility in Various Cancers
SAN DIEGO, December 15, 2010 – Amira Pharmaceuticals, Inc. announced today that it has successfully
identified a novel pre-clinical candidate for its newest lysophosphatidic
acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from
LPA receptors and has been implicated in a number of diseases including
rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid
cancers.
Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki
HELSINKI, December 15, 2010 – Esther Dyson and Anssi Vanjoki have invested in Valkee as part
of company's EUR 400,000 angel round. Valkee makes the bright light headset
to treat and prevent seasonal affective disorder and other depression types.
In clinical trials, 9 out of 10 patients have had symptoms relief in four
weeks, using Valkee 8-12 minutes …. Original article on Gaea Times at : Valkee Closes Angel Funding With Esther Dyson and Anssi Vanjoki.
Topical Market Research Reports by Future Markets Published at MarketPublishers.com
LONDON, December 16, 2010 – Market Publishers Ltd informs that new in-demand market
research reports by Future Markets, Inc (
marketpublishers.com/members/future_markets/info.html) have been added
to its catalogue.
Nanocoatings for the Aerospace Industry. This research presents a
detailed analysis of production methods and coating types, provides
information on market structures, market drivers and revenues. The research
presents detailed …. Source : Gaea News Network.
New Topical Research Reports by iData Research Published by MarketPublishers.com
LONDON, December 16, 2010 – Market Publishers Ltd informs that new in-demand market research
reports by iData Research
(marketpublishers.com/members/idata_research/info.html) have been
added to its catalogue.
Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology &
Ablation Devices 2011. In 2010, the Asia Pacific markets for cardiac rhythm
management (CRM), electrophysiology and ablation devices were valued at over
$1.4 billion. … Original source on Gaea Times at : New Topical Research Reports by iData Research Published by MarketPublishers.com.
Nice Supports the use of Low-Intensity Pulsed Ultrasound to Accelerate Bone Fracture Healing
Smith & Nephew's EXOGEN(TM) Ultrasound Bone Healing System Acknowledged as Efficacious and Safe Route to Rapid Recovery From Fractures
YORK, England, December 16, 2010 – The National Institute for Health and Clinical Excellence
(NICE) has advised healthcare professionals in the UK that the use of low
intensity pulsed ultrasound (LIPUS) technology represents a safe and
effective treatment option … Read this article on Gaea Times at : Nice Supports the use of Low-Intensity Pulsed Ultrasound to Accelerate Bone Fracture Healing.
Researchers Confirm Omega-3 EPA Required for Antidepressant Benefits
DARTMOUTH, Canada, December 16, 2010 – Researchers at the University of Illinois at Chicago completed a review
of previously published research on antidepressant benefits of Omega-3
essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). The review comprised a meta-analysis of 15 randomized, double-blind,
placebo-controlled studies in patients with depression and results were
presented at the recent annual … Original article on : Researchers Confirm Omega-3 EPA Required for Antidepressant Benefits.
COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
MURRIETA, California, December 16, 2010 – COPAN has enjoyed widespread use of its flocked swabs line, branded as
FLOQSwabs, in microbiology for the collection and transportation of bacterial
and viral samples.
FLOQSwabs by COPAN have been shown through numerous independent studies
to collect more sample and elute the entire sample thus improving the
detection and … Read more : COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs.
InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union
BRISBANE, California, December 17, 2010 – — Esbriet to be the first medicine approved for IPF patients in the EU –
InterMune, Inc. (Nasdaq: ITMN) today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) has adopted a positive opinion recommending the granting of a …. Original article : InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union.
InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy
Distinguished Panel Chaired by Dr. Martin B. Leon, From Columbia University Medical Center, Discuss Advancement of MGuard
TEL AVIV, Israel, December 17, 2010 – InspireMD, developer of the novel MGuard(TM), a combination of
a coronary stent merged with an embolic protection specifically designed for
Acute MI (AMI) patients, received significant exposure at the ICI,
Innovations in Interventional Cardiology, … Read the original article on Gaea Times at : InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy.
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe
BRISBANE, California, December 17, 2010 – — Conference call and webcast today at 8:30 a.m. EST to discuss positive
CHMP opinion –
InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior
leadership team to prepare for the commercialization of Esbriet(TM)
(pirfenidone) in Europe. InterMune's Marketing Authorization Application
(MAA) for Esbriet received a positive CHMP …. Original article on Gaea Times at : InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe.
Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
Recommendation Marks Taiho's First Regulatory Milestone Outside of Japan and Asia
TOKYO, December 17, 2010 – Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings
Co., Ltd., announced today that the Committee for Medicinal Products for
Human Use (CHMP), a division of the European Medicines Agency (EMA), has
issued an opinion recommending approval of Teysuno(TM) (S-1), a …. Original article on Gaea Times at : Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer.